We found that the inhibitor of the Rho/ROCK pathway ripasudil, a clinically approved drug for the treatment of glaucoma, mediated benefits to the normal actin turnover and rescued the ciliary defects associated with RPGR loss. Here, RPGR is linked to glaucoma.